While many bullish analysts and investors had previously mentioned the possibility of MAKO Surgical (MAKO) receiving an attractive buyout bid, the reality proved even better than expected. On Wednesday morning, MAKO and Stryker (SYK)
announced that the two companies had agreed on a deal that will see
Stryker buy MAKO for $30 share in cash - a $1.65 billion deal that
exceeded the highest sell-side price target on MAKO by 15%.
With
only scant odds that a rival bidder will top Stryker's offer, the MAKO
story comes to a relatively happy conclusion. What's more, Stryker would
seem to be an ideal partner to grow MAKO's business and maximize the
potential of the robot-assisted makoplasty concept.
To read more, please follow this link:
MAKO Surgical Gets Its Happy Ending
No comments:
Post a Comment